The myelodysplastic/myeloproliferative disorders: the interface.

Most patients with myelodysplastic syndromes can be identified easily and separated from patients who have myeloproliferative disorders. A few have overlapping features, however, with evidence of morphologic dysplasia and a proliferative advantage of one or more of the myeloid differentiating cell lines. For practical purposes and therapeutic considerations, chronic myelomonocytic leukemia is viewed now as a composite disorder along with atypical chronic myeloid leukemia and juvenile myelomonocytic leukemia.